Whole brain radiotherapy and RRx-001: Two partial responses in radioresistant melanoma brain metastases from a phase I/II clinical trial: A tite-crm phase I/II clinical trial

Michelle M. Kim, Hemant Parmar, Yue Cao, Priyanka Pramanik, Matthew Schipper, James Hayman, Larry Junck, Aaron Mammoser, Jason Heth, Corey A. Carter, Arnold Oronsky, Susan J. Knox, Scott Caroen, Bryan Oronsky, Jan Scicinski, Theodore S. Lawrence, Christopher D. Lao

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Kim et al. report two patients with melanoma metastases to the brain that responded to treatment with RRx-001 and whole brain radiotherapy (WBRT) without neurologic or systemic toxicity in the context of a phase I/II clinical trial. RRx-001 is an reactive oxygen and reactive nitrogen species (ROS/RNS)-dependent systemically nontoxic hypoxic cell radiosensitizer with vascular normalizing properties under investigation in patients with various solid tumors including those with brain metastases. SIGNIFICANCE: Metastatic melanoma to the brain is historically associated with poor outcomes and a median survival of 4 to 5 months. WBRT is a mainstay of treatment for patients with multiple brain metastases, but no significant therapeutic advances for these patients have been described in the literature. To date, candidate radiosensitizing agents have failed to demonstrate a survival benefit in patients with brain metastases, and in particular, no agent has demonstrated improved outcome in patients with metastatic melanoma. Kim et al. report two patients with melanoma metastases to the brain that responded to treatment with novel radiosensitizing agent RRx-001 and WBRT without neurologic or systemic toxicity in the context of a phase I/II clinical trial.

Original languageEnglish (US)
Pages (from-to)108-113
Number of pages6
JournalTranslational Oncology
Volume9
Issue number2
DOIs
StatePublished - Apr 1 2016
Externally publishedYes

Fingerprint

Phase II Clinical Trials
Clinical Trials, Phase I
Melanoma
Radiotherapy
Neoplasm Metastasis
Brain
Radiation-Sensitizing Agents
Nervous System
RRx-001
Reactive Nitrogen Species
Survival
Therapeutics
Blood Vessels
Oxygen

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Whole brain radiotherapy and RRx-001 : Two partial responses in radioresistant melanoma brain metastases from a phase I/II clinical trial: A tite-crm phase I/II clinical trial. / Kim, Michelle M.; Parmar, Hemant; Cao, Yue; Pramanik, Priyanka; Schipper, Matthew; Hayman, James; Junck, Larry; Mammoser, Aaron; Heth, Jason; Carter, Corey A.; Oronsky, Arnold; Knox, Susan J.; Caroen, Scott; Oronsky, Bryan; Scicinski, Jan; Lawrence, Theodore S.; Lao, Christopher D.

In: Translational Oncology, Vol. 9, No. 2, 01.04.2016, p. 108-113.

Research output: Contribution to journalArticle

Kim, MM, Parmar, H, Cao, Y, Pramanik, P, Schipper, M, Hayman, J, Junck, L, Mammoser, A, Heth, J, Carter, CA, Oronsky, A, Knox, SJ, Caroen, S, Oronsky, B, Scicinski, J, Lawrence, TS & Lao, CD 2016, 'Whole brain radiotherapy and RRx-001: Two partial responses in radioresistant melanoma brain metastases from a phase I/II clinical trial: A tite-crm phase I/II clinical trial', Translational Oncology, vol. 9, no. 2, pp. 108-113. https://doi.org/10.1016/j.tranon.2015.12.003
Kim, Michelle M. ; Parmar, Hemant ; Cao, Yue ; Pramanik, Priyanka ; Schipper, Matthew ; Hayman, James ; Junck, Larry ; Mammoser, Aaron ; Heth, Jason ; Carter, Corey A. ; Oronsky, Arnold ; Knox, Susan J. ; Caroen, Scott ; Oronsky, Bryan ; Scicinski, Jan ; Lawrence, Theodore S. ; Lao, Christopher D. / Whole brain radiotherapy and RRx-001 : Two partial responses in radioresistant melanoma brain metastases from a phase I/II clinical trial: A tite-crm phase I/II clinical trial. In: Translational Oncology. 2016 ; Vol. 9, No. 2. pp. 108-113.
@article{d6882bfdd9ab4d1f9220002a70759cce,
title = "Whole brain radiotherapy and RRx-001: Two partial responses in radioresistant melanoma brain metastases from a phase I/II clinical trial: A tite-crm phase I/II clinical trial",
abstract = "BACKGROUND: Kim et al. report two patients with melanoma metastases to the brain that responded to treatment with RRx-001 and whole brain radiotherapy (WBRT) without neurologic or systemic toxicity in the context of a phase I/II clinical trial. RRx-001 is an reactive oxygen and reactive nitrogen species (ROS/RNS)-dependent systemically nontoxic hypoxic cell radiosensitizer with vascular normalizing properties under investigation in patients with various solid tumors including those with brain metastases. SIGNIFICANCE: Metastatic melanoma to the brain is historically associated with poor outcomes and a median survival of 4 to 5 months. WBRT is a mainstay of treatment for patients with multiple brain metastases, but no significant therapeutic advances for these patients have been described in the literature. To date, candidate radiosensitizing agents have failed to demonstrate a survival benefit in patients with brain metastases, and in particular, no agent has demonstrated improved outcome in patients with metastatic melanoma. Kim et al. report two patients with melanoma metastases to the brain that responded to treatment with novel radiosensitizing agent RRx-001 and WBRT without neurologic or systemic toxicity in the context of a phase I/II clinical trial.",
author = "Kim, {Michelle M.} and Hemant Parmar and Yue Cao and Priyanka Pramanik and Matthew Schipper and James Hayman and Larry Junck and Aaron Mammoser and Jason Heth and Carter, {Corey A.} and Arnold Oronsky and Knox, {Susan J.} and Scott Caroen and Bryan Oronsky and Jan Scicinski and Lawrence, {Theodore S.} and Lao, {Christopher D.}",
year = "2016",
month = "4",
day = "1",
doi = "10.1016/j.tranon.2015.12.003",
language = "English (US)",
volume = "9",
pages = "108--113",
journal = "Translational Oncology",
issn = "1936-5233",
publisher = "Neoplasia Press",
number = "2",

}

TY - JOUR

T1 - Whole brain radiotherapy and RRx-001

T2 - Two partial responses in radioresistant melanoma brain metastases from a phase I/II clinical trial: A tite-crm phase I/II clinical trial

AU - Kim, Michelle M.

AU - Parmar, Hemant

AU - Cao, Yue

AU - Pramanik, Priyanka

AU - Schipper, Matthew

AU - Hayman, James

AU - Junck, Larry

AU - Mammoser, Aaron

AU - Heth, Jason

AU - Carter, Corey A.

AU - Oronsky, Arnold

AU - Knox, Susan J.

AU - Caroen, Scott

AU - Oronsky, Bryan

AU - Scicinski, Jan

AU - Lawrence, Theodore S.

AU - Lao, Christopher D.

PY - 2016/4/1

Y1 - 2016/4/1

N2 - BACKGROUND: Kim et al. report two patients with melanoma metastases to the brain that responded to treatment with RRx-001 and whole brain radiotherapy (WBRT) without neurologic or systemic toxicity in the context of a phase I/II clinical trial. RRx-001 is an reactive oxygen and reactive nitrogen species (ROS/RNS)-dependent systemically nontoxic hypoxic cell radiosensitizer with vascular normalizing properties under investigation in patients with various solid tumors including those with brain metastases. SIGNIFICANCE: Metastatic melanoma to the brain is historically associated with poor outcomes and a median survival of 4 to 5 months. WBRT is a mainstay of treatment for patients with multiple brain metastases, but no significant therapeutic advances for these patients have been described in the literature. To date, candidate radiosensitizing agents have failed to demonstrate a survival benefit in patients with brain metastases, and in particular, no agent has demonstrated improved outcome in patients with metastatic melanoma. Kim et al. report two patients with melanoma metastases to the brain that responded to treatment with novel radiosensitizing agent RRx-001 and WBRT without neurologic or systemic toxicity in the context of a phase I/II clinical trial.

AB - BACKGROUND: Kim et al. report two patients with melanoma metastases to the brain that responded to treatment with RRx-001 and whole brain radiotherapy (WBRT) without neurologic or systemic toxicity in the context of a phase I/II clinical trial. RRx-001 is an reactive oxygen and reactive nitrogen species (ROS/RNS)-dependent systemically nontoxic hypoxic cell radiosensitizer with vascular normalizing properties under investigation in patients with various solid tumors including those with brain metastases. SIGNIFICANCE: Metastatic melanoma to the brain is historically associated with poor outcomes and a median survival of 4 to 5 months. WBRT is a mainstay of treatment for patients with multiple brain metastases, but no significant therapeutic advances for these patients have been described in the literature. To date, candidate radiosensitizing agents have failed to demonstrate a survival benefit in patients with brain metastases, and in particular, no agent has demonstrated improved outcome in patients with metastatic melanoma. Kim et al. report two patients with melanoma metastases to the brain that responded to treatment with novel radiosensitizing agent RRx-001 and WBRT without neurologic or systemic toxicity in the context of a phase I/II clinical trial.

UR - http://www.scopus.com/inward/record.url?scp=84963585101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963585101&partnerID=8YFLogxK

U2 - 10.1016/j.tranon.2015.12.003

DO - 10.1016/j.tranon.2015.12.003

M3 - Article

C2 - 27084426

AN - SCOPUS:84963585101

VL - 9

SP - 108

EP - 113

JO - Translational Oncology

JF - Translational Oncology

SN - 1936-5233

IS - 2

ER -